ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

IBRX ImmunityBio Inc

9.07
0.10 (1.11%)
May 03 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 14,704,253
Bid Price 9.07
Ask Price 9.12
News -
Day High 10.01

Low
1.25

52 Week Range

High
10.53

Day Low 8.645
Company Name Stock Ticker Symbol Market Type
ImmunityBio Inc IBRX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.10 1.11% 9.07 19:59:42
Open Price Low Price High Price Close Price Prev Close
9.48 8.645 10.01 9.15 8.97
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
75,594 14,704,253 $ 9.17 $ 134,844,414 - 1.25 - 10.53
Last Trade Time Type Quantity Stock Price Currency
19:59:58 50 $ 9.07 USD

ImmunityBio (IBRX) Options Flow Summary

Overall Flow

Bullish

Net Premium

572k

Calls / Puts

156.25%

Buys / Sells

131.25%

OTM / ITM

105.00%

Sweeps Ratio

0.02%

ImmunityBio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
21.69B 667.71M - 622k -583.2M -0.87 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

ImmunityBio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IBRX Message Board. Create One! See More Posts on IBRX Message Board See More Message Board Posts

Historical IBRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.1110.534.92018.3928,718,6983.9677.50%
1 Month5.6210.534.737.1811,960,0723.4561.39%
3 Months4.3310.533.376.267,070,1294.74109.47%
6 Months3.7010.532.6655.315,591,3565.37145.14%
1 Year3.0710.531.254.165,018,4326.00195.44%
3 Years17.1518.13991.214.692,908,591-8.08-47.11%
5 Years36.5540.8341.215.092,827,307-27.48-75.18%

ImmunityBio Description

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.

Your Recent History

Delayed Upgrade Clock